Fig. 3.

Effect of statins on soluble endoglin secretion from primary human tissues. a Simvastatin (0, 1, 2, 5 μM), rosuvastatin (0, 1, 2, 5, μM) and pravastatin (0, 2, 5, 200 μM) all caused an increase in soluble endoglin secretion from primary HUVECs. b Statin treatment did not alter sEng secretion from preterm preeclamptic explants. Data represents n = 3–4 separate experiments and is expressed as mean ± SEM. Dark blue bars = control, light blue bars = statin treatments. a = p < 0.05, b = p < 0.01, d = p < 0.0001